Transplant using Belatacept to Prevent Organ Transplant Rejection

Emory physicians played a leading role in the development of belatacept, a new immuno-suppressant drug recently approved by the U.S. Food and Drug Administration (FDA). Belatacept helps prevent organ rejection with fewer side effects following kidney transplantation. The new drug has the potential to improve long-term survival and simplify the medication regimens of kidney transplant recipients. Learn more about Belatacept from Emory physicians and a patient experience.